Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
27.75
-0.37 (-1.32%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Dianthus Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 4.12 | 2.83 | 6.42 | 1.48 |
| Revenue Growth (YoY) | 8.57% | -55.96% | 334.76% | - |
| Gross Profit | 4.12 | 2.83 | 6.42 | 1.48 |
| Selling, General & Admin | 24.99 | 18.16 | 6.74 | 1.96 |
| Research & Development | 47.89 | 32.84 | 29.38 | 12.61 |
| Operating Expenses | 72.88 | 51 | 36.12 | 14.56 |
| Operating Income | -68.76 | -48.17 | -29.71 | -13.09 |
| Interest & Investment Income | 12.4 | 4.76 | 1.15 | 0 |
| Currency Exchange Gain (Loss) | -0.09 | -0.09 | 0.14 | -0.03 |
| Other Non Operating Income (Expenses) | -0.23 | -0.06 | -0.05 | - |
| Pretax Income | -56.68 | -43.56 | -28.48 | -13.11 |
| Net Income | -56.68 | -43.56 | -28.48 | -13.11 |
| Net Income to Common | -56.68 | -43.56 | -28.48 | -13.11 |
| Shares Outstanding (Basic) | 21 | 5 | 1 | 4 |
| Shares Outstanding (Diluted) | 21 | 5 | 1 | 4 |
| Shares Change (YoY) | 413.54% | 489.48% | -78.18% | - |
| EPS (Basic) | -2.75 | -8.45 | -32.57 | -3.27 |
| EPS (Diluted) | -2.75 | -8.45 | -32.57 | -3.27 |
| Free Cash Flow | -51.44 | -36.97 | -29.21 | -9.94 |
| Free Cash Flow Per Share | -2.50 | -7.17 | -33.41 | -2.48 |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Margin | -1669.82% | -1704.67% | -462.91% | -886.59% |
| Profit Margin | -1376.42% | -1541.22% | -443.76% | -888.14% |
| Free Cash Flow Margin | -1249.13% | -1308.24% | -455.18% | -673.24% |
| EBITDA | -68.68 | -48.11 | -29.68 | - |
| D&A For EBITDA | 0.08 | 0.07 | 0.03 | - |
| EBIT | -68.76 | -48.17 | -29.71 | -13.09 |
Source: S&P Capital IQ. Standard template.
Financial Sources.